• IRIS26: Avoidance of routine antibiotic use in patients before or after intravitreal injections


    Updated January 2018.

    Reporting Options:

    • IRIS Registry QCDR manual data entry: groups and individuals

    Measure Type: Appropriate Use

    Description:  The percentage of patients, aged 18 years and older, who received topical or systemic antibiotics before or after intravitreal injections

    To Which Patients Does the Measure Apply?

    Denominator: Patients aged 18 years or older who received topical or systemic antibiotics before or after intravitreal injections, except for endophthalmitis

    There are two criteria for inclusion of a patient into the denominator.

    1. Patient characteristics: Description located in “Denominator” (see above)
    2. Procedure codes (CPT): Codes located in “CPT Codes” 

    CPT Codes

    Intravitreal injections in eyes without endophthalmitis

    • Bevacizumab (Avastin®) injections: 67028, J9035, J3490, J3590, C9257 
    • Ranibizumab (Lucentis®) injections: 67028, J2778
    • Aflibercept (EYLEA®) injections: 67028, J0178
    • Fluocinolone acetonide (Iluvien) injections: 67028, J7311
    • Dexamethasone (Ozurdex) injections: 67028, J7312
    • Triamcinalone (Kenalog) injections: 67028, J3301
    • Triamcinolone acetonide  (Triesence) injections: 67028, J3300

    How to Report the Measure

    Numerator: Patients who received antibiotics before or after intravitreal injections (same day). 

    Benchmarks

    • No scoring benchmark currently exists for this QCDR measure.
    • If 19 or fewer physicians each report the measure or 20 physicians do not report the measure on at least 60 percent of qualifying patients, and a minimum of 20 patients, you will earn 3 out of 10 points toward your total quality score. Choose measures assuming you’ll only earn 3 points per QCDR measure.
    • If at least 20 physicians report the measure on at least 60 percent of qualifying patients and at least 20 patients, CMS will develop a scoring benchmark using data collected during the 2018 reporting year.

    Copyright

    This measure has been developed by the H. Dunbar Hoskins Jr. MD Center for Quality Eye Care of the American Academy of Ophthalmology. The measure is not a clinical guideline and does not establish a medical standard. It has not been tested in all possible applications.

    The measure, while copyrighted, can be reproduced and distributed with appropriate credit, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. The American Academy of Ophthalmology encourages use of the measure by other health care professionals, where applicable.

    Commercial use is defined as the sale, license or distribution of the measures for commercial gain, or incorporation of some or all of a measure into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the measures require a license agreement between the user and the American Academy of Ophthalmology. Neither the Academy nor its members shall be responsible for any use of the measures. 

    THE MEASURE AND SPECIFICATIONS ARE PROVIDED “AS IS,” WITHOUT WARRANTY OF ANY KIND.

    © 2017 American Academy of Ophthalmology. All rights reserved. Limited proprietary coding from Current Procedural Terminology (CPT®) is contained in the measure specifications. Users of this code set should obtain all necessary licenses. The Academy disclaims all liability for use or accuracy of the coding contained in these measure specifications. CPT® contained in the measures specifications is copyright 2004-2017 American Medical Association.